Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma

Background & Aims Tumour mutational burden (TMB) predicts improved response and survival to immunotherapy. In this pilot study, we optimized targeted next‐generation sequencing (tNGS) to estimate TMB in hepatocellular carcinoma (HCC). Methods We sequenced 48 non‐paired samples (21 fresh‐frozen [...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Liver international 2021-01, Vol.41 (1), p.192-203
Hauptverfasser:	Wong, Ching Ngar, Fessas, Petros, Dominy, Kathy, Mauri, Francesco A., Kaneko, Takahiro, Parcq, Persephone Du, Khorashad, Jamshid, Toniutto, Pierluigi, Goldin, Robert D., Avellini, Claudio, Pinato, David J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Biomarkers, Tumor - genetics Carcinoma, Hepatocellular - genetics CpG islands Deamination Deoxyribonucleic acid DNA DNA glycosylase DNA sequencing Gene frequency Hepatocellular carcinoma High-Throughput Nucleotide Sequencing Humans Immunotherapy Liver cancer Liver Neoplasms - genetics Mutation Paraffin Paraffins Pilot Projects Quality control Survival Tumors tumour mutational burden Uracil
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!